Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of$ 0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of$ 0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company h ...